Acquisition by David Woodhouse of 127200 shares of NGM Biopharmaceutica subject to Rule 16b-3

Read at macroaxis.com

Published over a year ago View all stories for NGM Biopharmaceutica | NGM Biopharmaceutica Hype Analysis

NGM Biopharmaceutica insider trading alert for grant of common stock by David Woodhouse, Chief Executive Officer, on 6th of March 2023. This event was filed by Ngm Biopharmaceuticals In with SEC on 2023-03-06. Statement of changes in beneficial ownership - SEC Form 4

We analyze NGM Biopharmaceutica's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NGM Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NGM Biopharmaceutica based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NGM Biopharmaceutica stock to make a market-neutral strategy. Peer analysis of NGM Biopharmaceutica could also be used in its relative valuation, which is a method of valuing NGM Biopharmaceutica by comparing valuation metrics with similar companies.

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Stocks Directory module to find actively traded stocks across global markets.

If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.